ERBB2 and breast carcinoma: For example, folate-modified liposomes selectively target folate receptors, which are overexpressed in ovarian and breast cancers [135], while HER2-targeted liposomes, conjugated with trastuzumab, enhancing drug uptake in HER2-positive breast cancer [136].